|
1
|
Evans A: Neuroblastoma: A historical
perspective 1864–1998Neuroblastoma. Brodeur GM, Sawada T, Tsuchida
Y and Voûte PA: Elsevier Science; Amsterdam: pp. 1–7. 2000
|
|
2
|
Yáñez Y, Grau E, Rodríguez-Cortez VC,
Hervás D, Vidal E, Noguera R, Hernández M, Segura V, Cañete A,
Conesa A, et al: Two independent epigenetic biomarkers predict
survival in neuroblastoma. Clin Epigenetics. 7:162015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
London WB, Castleberry RP, Matthay KK,
Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM,
Reynolds CP and Cohn SL: Evidence for an age cutoff greater than
365 days for neuroblastoma risk group stratification in the
children's oncology group. J Clin Oncol. 23:6459–6465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Look AT, Hayes FA, Shuster JJ, Douglass
EC, Castleberry RP, Bowman LC, Smith EI and Brodeur GM: Clinical
relevance of tumor cell ploidy and N-myc gene amplification in
childhood neuroblastoma: A pediatric oncology group study. J Clin
Oncol. 9:581–591. 1991.PubMed/NCBI
|
|
5
|
Caron H: Allelic loss of chromosome 1 and
additional chromosome 17 material are both unfavourable prognostic
markers in neuroblastoma. Med Pediatr Oncol. 24:215–221. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lampert F, Rudolph B, Christiansen H and
Franke F: Identical chromosome 1p breakpoint abnormality in both
the tumor and the constitutional karyotype of a patient with
neuroblastoma. Cancer Genet Cytogenet. 34:235–239. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cohn SL, Pearson AD, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: The international neuroblastoma risk group (INRG)
classification system: An INRG task force report. J Clin Oncol.
27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spitz R, Hero B, Simon T and Berthold F:
Loss in chromosome 11q identifies tumors with increased risk for
metastatic relapses in localized and 4S neuroblastoma. Clin Cancer
Res. 12:3368–3373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castleberry RP: Consistently investigating
the inconsistent nature of neuroblastoma. J Pediatr Hematol Oncol.
21:178–180. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Irwin MS and Park JR: Neuroblastoma:
Paradigm for precision medicine. Pediatr Clin North Am. 62:225–256.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Monclair T, Brodeur GM, Ambros PF, Brisse
HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK,
Nuchtern JG, et al: The international neuroblastoma risk group
(INRG) staging system: An INRG task force report. J Clin Oncol.
27:298–303. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brodeur GM, Seeger RC, Schwab M, Varmus HE
and Bishop JM: Amplification of N-myc in untreated human
neuroblastomas correlates with advanced disease stage. Science.
224:1121–1124. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seeger RC, Brodeur GM, Sather H, Dalton A,
Siegel SE, Wong KY and Hammond D: Association of multiple copies of
the N-myc oncogene with rapid progression of neuroblastomas. N Engl
J Med. 313:1111–1116. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimada H, Ambros IM, Dehner LP, Hata J,
Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, et
al: The international neuroblastoma pathology classification (the
Shimada system). Cancer. 86:364–372. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng JM, Hiemstra JL, Schneider SS,
Naumova A, Cheung NK, Cohn SL, Diller L, Sapienza C and Brodeur GM:
Preferential amplification of the paternal allele of the N-myc gene
in human neuroblastomas. Nat Genet. 4:191–194. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Landier W, Bhatia S, Eshelman DA, Forte
KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J,
Constine LS, et al: Development of risk-based guidelines for
pediatric cancer survivors: the Children's Oncology Group Long-Term
Follow-Up Guidelines from the Children's Oncology Group Late
Effects Committee and Nursing Discipline. J Clin Oncol.
22:4979–4990. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Malogolowkin MH, Katzenstein HM, Krailo M,
Chen Z, Quinn JJ, Reynolds M and Ortega JA: Redefining the role of
doxorubicin for the treatment of children with hepatoblastoma. J
Clin Oncol. 26:2379–2383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Franklin HR, Simonetti GP, Dubbelman AC,
ten Bokkel Huinink WW, Taal BG, Wigbout G, Mandjes IA, Dalesio OB
and Aaronson NK: Toxicity grading systems. A comparison between the
WHO scoring system and the Common Toxicity Criteria when used for
nausea and vomiting. Ann Oncol. 5:113–117. 1994.PubMed/NCBI
|
|
20
|
Brodeur GM, Seeger RC, Barrett A, Berthold
F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M,
Freeman AI, et al: International criteria for diagnosis, staging,
and response to treatment in patients with neuroblastoma. J Clin
Oncol. 6:1874–1881. PubMed/NCBI
|
|
21
|
Cohn SL, Pearson AD, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: The International Neuroblastoma Risk Group (INRG)
classification system: an INRG Task Force report. J Clin Oncol.
27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dumba M, Jawad N and McHugh K:
Neuroblastoma and nephroblastoma: A radiological review. Cancer
Imaging. 15:52015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schleiermacher G, Rubie H, Hartmann O,
Bergeron C, Chastagner P, Mechinaud F and Michon J: Neuroblastoma
Study Group of the French Society of Paediatric Oncology: Treatment
of stage 4s neuroblastoma-report of 10 years' experience of the
French Society of Paediatric Oncology (SFOP). Br J Cancer.
89:470–476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hiyama E, Iehara T, Sugimoto T, Fukuzawa
M, Hayashi Y, Sasaki F, Sugiyama M, Kondo S, Yoneda A, Yamaoka H,
et al: Effectiveness of screening for neuroblastoma at 6 months of
age: a retrospective population-based cohort study. Lancet.
371:1173–1180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kushner BH, Modak S, Kramer K, LaQuaglia
MP, Yataghene K, Basu EM, Roberts SS and Cheung NK: Striking
dichotomy in outcome of MYCN-amplified neuroblastoma in the
contemporary era. Cancer. 120:2050–2059. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ando S, Suzuki M, Yamamoto N, Iida T and
Kimura H: The prognostic value of both neuron-specific enolase
(NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res.
24:1941–1946. 2004.PubMed/NCBI
|
|
27
|
Karnak D, Beder S, Kayacan O, Ibis E and
Oflaz G: Neuron-specific enolase and lung cancer. Am J Clin Oncol.
28:586–590. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tapia FJ, Polak JM, Barbosa AJ, Bloom SR,
Marangos PJ, Dermody C and Pearse AG: Neuron-specific enolase is
produced by neuroendocrine tumours. Lancet. 1:808–811. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gallagher KK, Spector ME, Pepper JP,
McKean EL, Marentette LJ and McHugh JB: Esthesioneuroblastoma:
Updating histologic grading as it relates to prognosis. Ann Otol
Rhinol Laryngol. 123:353–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vo KT, Matthay KK, Neuhaus J, London WB,
Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD,
et al: Clinical, biologic, and prognostic differences on the basis
of primary tumor site in neuroblastoma: A report from the
international neuroblastoma risk group project. J Clin Oncol.
32:3169–3176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stram DO, Matthay KK, O'Leary M, Reynolds
CP, Haase GM, Atkinson JB, Brodeur GM and Seeger RC: Consolidation
chemoradiotherapy and autologous bone marrow transplantation versus
continued chemotherapy for metastatic neuroblastoma: A report of
two concurrent children's cancer group studies. J Clin Oncol.
14:2417–2426. 1996.PubMed/NCBI
|
|
32
|
Vogelzang NJ, Benowitz SI, Adams S,
Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA,
Odenike O, et al: Clinical cancer advances 2011: Annual report on
progress against cancer from the American society of clinical
oncology. J Clin Oncol. 30:88–109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akramipour R, Zargooshi J and Rahimi Z:
Infant with concomitant presence of hernia/hydrocele and primary
paratesticular neuroblastoma: A diagnostic and therapeutic
challenge. J Pediatr Hematol Oncol. 31:3492009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nuchtern JG, London WB, Barnewolt CE,
Naranjo A, McGrady PW, Geiger JD, Diller L, Schmidt ML, Maris JM,
Cohn SL and Shamberger RC: A prospective study of expectant
observation as primary therapy for neuroblastoma in young infants:
A children's oncology group study. Ann Surg. 256:573–580. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Capasso M, Cinalli G, Nastro A, Giuliano
M, Errico ME, Caccioppoli U, Turco R, Ruotolo S, Vetrella S, De
Bernardi B, et al: Symptomatic epidural compression in infants with
neuroblastoma: A single-center experience with 5 cases. J Pediatr
Hematol Oncol. 35:260–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
